Press Release & Publications


Allgenesis Program Selected for RESI Taipei Innovation Challenge

Taipei, Taiwan/ November 14th, 2019 Allg […]

Allgenesis sees Excellent Safety, Tolerability, and Signs of Efficacy from its Ongoing POC Phase 2a Study of AG-86893 in Patients with Pterygium

Taipei, Taiwan/ October 18th, 2019 Allge […]

Allgenesis Provides Timing Update of SURPH Phase 2a Clinical Trial for AG-86893 for the Treatment of Pterygium

September 25th, 2019 Allgenesis Biothera […]

CEO Dr. Cherukury Interviewed by Macular Degeneration Foundation at the 2019 ARVO Conference

June 11th, 2019 Allgenesis In the News: […]

Phase 2a SURPH Trial for AG-86893

May 24th, 2019 Allgenesis In The News: A […]

Allgenesis Presented Three Posters at ARVO 2019

May 4th, 2019 Allgenesis attended the 20 […]